Auro Laboratories' Q2 financial report shows mixed results, with declining sales and profits.

Auro Laboratories, a microcap pharmaceutical company, recently declared its financial results for the quarter ending September 2024. The company's stock has been given a 'Sell' call by MarketsMOJO.

According to the financial report, Auro Labs. has seen a negative performance in the second quarter of the fiscal year 2024-2025. The company's score has fallen from -1 to -11 in the last three months.

However, there are some positive aspects to the company's financials. Auro Labs. has shown a strong operating cash flow, with the highest annual amount of Rs 18.81 crore and consistent growth over the past three years. This indicates that the company has been able to generate higher cash revenues from its business operations.

On the other hand, there are some concerning factors as well. The net sales for the first half of the year have decreased by 62.61% compared to the previous year, indicating a negative sales trend in the near term. Similarly, the profit after tax has also decreased by 58.58% year on year, showing a negative trend in the near term.

The company's operating profit and profit before tax less other income have also been on a decline in the last five quarters, with the lowest figures being recorded in the most recent quarter. This suggests a negative trend in the near term for both these financial indicators.

In addition, Auro Labs.'s earnings per share have also decreased in the last five quarters, with the lowest figure being Rs 0.58. This indicates a declining profitability and lower earnings for shareholders.

Overall, Auro Laboratories' financial results for the quarter ending September 2024 have shown a mix of positive and negative trends. Investors should carefully consider these factors before making any investment decisions.